Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Advanced Parkinson's Disease: full-pipeline trial registry
1 of 4 indexed Advanced Parkinson's Disease trials are currently recruiting.
Corpus placement: #4,115 of 28,707 conditions by registered trial count.
4 US clinical trials · 1 currently recruiting · #4,115 of 28,707 conditions by registered trial count
Advanced Parkinson's Disease: 4 US clinical trials tracked, 1 recruiting.
Advanced Parkinson's Disease is the subject of 4 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is AbbVie, running 2 of these trials.
Enrollment posture brief
Registry condition advanced-parkinsons-disease
OPEN 1 | RECR 25% | LATE 2 | EARLY 2 | RANK #4115 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Abdominal Cancer (25% recruiting · 8 trials)
Advanced Parkinson's Disease lists 1 open slots (25% of 4 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Advanced Parkinson's Disease on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Advanced Parkinson's Disease is recruiting below its size-band peers.
1 of 4 indexed trials (25%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
4 total, page 1 of 1
SAD Study in Patients With Parkinson's Disease and Motor Fluctuations
Serina Therapeutics
NCT07422675
Open Label Continuation Treatment Study With Levodopa-Carbidopa Intestinal Gel in Advanced Parkinson's Disease
AbbVie
NCT00660673
A Study to Examine the Effect of Levodopa-Carbidopa Intestinal Gel (LCIG) Therapy Relative to That of Optimized Medical Treatment (OMT) on Non-motor Symptoms (NMS) Associated With Advanced Parkinson's Disease (PD)
AbbVie
NCT02549092
Phase 1 Safety and Tolerability Study of MSK-DA01 Cell Therapy for Advanced Parkinson's Disease
BlueRock Therapeutics
NCT04802733
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 3 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Advanced Parkinson's Disease records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Advanced Parkinson's Disease trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Advanced Parkinson's Disease page
4 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 1 Advanced Parkinson's Disease trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- AbbVie sponsors the most Advanced Parkinson's Disease trials on record, review their full trial history before evaluating a specific study. See AbbVie's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Advanced Parkinson's Disease condition card totals 4 registered trials; most-linked intervention MSK-DA01 Cell Delivery Device; top US site state Florida. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.